Head-To-Head Review: Inhibitor Therapeutics (OTCMKTS:INTI) & Anavex Life Sciences (NASDAQ:AVXL)
Inhibitor Therapeutics (OTCMKTS:INTI) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Analyst Ratings
This is a summary of current ratings for Inhibitor Therapeutics and Anavex Life Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibitor Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Anavex Life Sciences | 0 | 0 | 5 | 0 | 3.00 |
Profitability
This table compares Inhibitor Therapeutics and Anavex Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibitor Therapeutics | N/A | N/A | -405.02% |
| Anavex Life Sciences | N/A | -102.39% | -81.73% |
Risk and Volatility
Inhibitor Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
Valuation and Earnings
This table compares Inhibitor Therapeutics and Anavex Life Sciences’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibitor Therapeutics | N/A | N/A | -$2.73 million | N/A | N/A |
| Anavex Life Sciences | N/A | N/A | -$26.28 million | ($0.45) | -34.07 |
Insider & Institutional Ownership
18.9% of Anavex Life Sciences shares are held by institutional investors. 4.6% of Inhibitor Therapeutics shares are held by insiders. Comparatively, 12.4% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Anavex Life Sciences beats Inhibitor Therapeutics on 6 of the 8 factors compared between the two stocks.
Inhibitor Therapeutics Company Profile
Inhibitor Therapeutics Inc. operates as a pharmaceutical development company that discovers, develops, and plans to commercialize therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders in the United States. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity, and cell proliferation. It focuses on developing its lead product, SUBA-Itraconazole, a patented oral formulation for prostate and lung cancer. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics Inc. in August 2019. Inhibitor Therapeutics Inc. was founded in 1992 and is based in Tampa, Florida.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Receive News & Ratings for Inhibitor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibitor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
